Avalon Advisors Decreased Its Bristol (BMY) Stake; 7 Analysts Bullish Revance Therapeutics (RVNC)

November 15, 2017 - By Nellie Frank

Among 8 analysts covering Revance Therapeutics (NASDAQ:RVNC), 7 have Buy rating, 0 Sell and 1 Hold. Therefore 88% are positive. Revance Therapeutics had 13 analyst reports since August 22, 2015 according to SRatingsIntel. Aegis Capital maintained the stock with “Buy” rating in Thursday, June 8 report. The firm has “Buy” rating by SunTrust given on Wednesday, March 23. The firm has “Buy” rating given on Monday, November 23 by Guggenheim. Brean Capital downgraded the stock to “Hold” rating in Tuesday, June 14 report. As per Tuesday, July 25, the company rating was maintained by Piper Jaffray. The rating was maintained by Cantor Fitzgerald on Thursday, November 2 with “Buy”. On Tuesday, June 14 the stock rating was maintained by Suntrust Robinson with “Buy”. The firm earned “Buy” rating on Tuesday, November 29 by Aegis Capital. As per Thursday, July 20, the company rating was initiated by Cantor Fitzgerald. The stock of Revance Therapeutics Inc (NASDAQ:RVNC) earned “Buy” rating by Cantor Fitzgerald on Tuesday, October 24. See Revance Therapeutics Inc (NASDAQ:RVNC) latest ratings:

02/11/2017 Broker: SunTrust Rating: Buy New Target: $32.0 Maintain
02/11/2017 Broker: Cantor Fitzgerald Rating: Buy New Target: $50.0 Maintain
24/10/2017 Broker: Cantor Fitzgerald Rating: Buy New Target: $50.0 Maintain
22/08/2017 Broker: JMP Securities Rating: Market Outperform New Target: $34 Initiates Coverage On
25/07/2017 Broker: Piper Jaffray Rating: Buy New Target: $28.0000 Maintain
20/07/2017 Broker: Cantor Fitzgerald Rating: Buy New Target: $50.0000 Initiate
08/06/2017 Broker: Aegis Capital Rating: Buy New Target: $36.0000 Maintain

Avalon Advisors Llc decreased Bristol (BMY) stake by 89.42% reported in 2017Q2 SEC filing. Avalon Advisors Llc sold 160,290 shares as Bristol (BMY)’s stock declined 1.04%. The Avalon Advisors Llc holds 18,962 shares with $1.06M value, down from 179,252 last quarter. Bristol now has $99.50 billion valuation. The stock declined 0.75% or $0.46 reaching $60.79 per share. About 154,408 shares traded. Bristol-Myers Squibb Co (NYSE:BMY) has declined 23.19% since November 15, 2016 and is downtrending. It has underperformed by 39.89% the S&P500.

Investors sentiment decreased to 0.95 in 2017 Q2. Its down 0.03, from 0.98 in 2017Q1. It turned negative, as 78 investors sold BMY shares while 520 reduced holdings. 120 funds opened positions while 451 raised stakes. 1.10 billion shares or 2.26% less from 1.12 billion shares in 2017Q1 were reported. Sheets Smith Wealth Mgmt invested 0.24% in Bristol-Myers Squibb Co (NYSE:BMY). New South Management invested in 0.01% or 8,312 shares. Hanson And Doremus Inv invested 0.7% of its portfolio in Bristol-Myers Squibb Co (NYSE:BMY). Apriem Advsrs holds 0.07% or 5,047 shares. Fiduciary Fincl Svcs Of The Southwest Tx reported 144,133 shares. Macquarie Grp Inc Ltd has 0.03% invested in Bristol-Myers Squibb Co (NYSE:BMY). 361,618 are held by Williams Jones And Assoc. First Merchants Corp owns 0.13% invested in Bristol-Myers Squibb Co (NYSE:BMY) for 8,660 shares. Tru Department Mb National Bank & Trust N A has invested 0% in Bristol-Myers Squibb Co (NYSE:BMY). Fukoku Mutual Life Ins holds 0.84% or 102,190 shares. Altfest L J & holds 1.91% or 56,910 shares in its portfolio. Burt Wealth Advisors holds 0.27% or 6,967 shares in its portfolio. Voloridge Invest Mgmt Limited Liability Co accumulated 0.54% or 388,217 shares. Southeast Asset holds 0.11% or 6,155 shares in its portfolio. First Heartland Consultants holds 0.1% or 6,839 shares in its portfolio.

Among 19 analysts covering Bristol-Myers Squibb Company (NYSE:BMY), 6 have Buy rating, 3 Sell and 10 Hold. Therefore 32% are positive. Bristol-Myers Squibb Company had 67 analyst reports since July 28, 2015 according to SRatingsIntel. Citigroup maintained Bristol-Myers Squibb Co (NYSE:BMY) on Wednesday, October 18 with “Buy” rating. The firm has “Market Perform” rating given on Monday, January 25 by BMO Capital Markets. The stock of Bristol-Myers Squibb Co (NYSE:BMY) earned “Neutral” rating by Hilliard Lyons on Monday, May 23. The company was upgraded on Monday, August 24 by Piper Jaffray. Guggenheim upgraded the stock to “Buy” rating in Wednesday, December 2 report. The stock of Bristol-Myers Squibb Co (NYSE:BMY) earned “Buy” rating by Jefferies on Monday, July 17. The rating was upgraded by SunTrust on Monday, October 30 to “Buy”. The stock of Bristol-Myers Squibb Co (NYSE:BMY) has “Underweight” rating given on Friday, December 18 by Atlantic Securities. The stock of Bristol-Myers Squibb Co (NYSE:BMY) has “Equal-Weight” rating given on Friday, August 5 by Morgan Stanley. On Friday, October 13 the stock rating was maintained by Barclays Capital with “Equal-Weight”.

Analysts await Bristol-Myers Squibb Co (NYSE:BMY) to report earnings on January, 25. They expect $0.67 earnings per share, up 6.35% or $0.04 from last year’s $0.63 per share. BMY’s profit will be $1.10 billion for 22.68 P/E if the $0.67 EPS becomes a reality. After $0.75 actual earnings per share reported by Bristol-Myers Squibb Co for the previous quarter, Wall Street now forecasts -10.67% negative EPS growth.

Avalon Advisors Llc increased Russell 2000 Ishares Etf (IWM) stake by 2,608 shares to 18,375 valued at $2.59 million in 2017Q2. It also upped Heico Corp New Com (NYSE:HEI) stake by 8,656 shares and now owns 41,424 shares. Xpo Logistics Inc (NYSE:XPO) was raised too.

Since May 22, 2017, it had 0 buys, and 2 sales for $685,462 activity. $649,250 worth of Revance Therapeutics Inc (NASDAQ:RVNC) was sold by Browne L Daniel. SILVERNAIL LAUREN P also sold $36,212 worth of Revance Therapeutics Inc (NASDAQ:RVNC) on Monday, May 22.

Revance Therapeutics, Inc. is a clinical-stage biotechnology company. The company has market cap of $773.37 million. The Firm is focused on the development, manufacturing and commercialization of botulinum toxin products for multiple aesthetic and therapeutic indications. It currently has negative earnings. The Company’s peptide technology enables delivery of botulinum toxin type A through two investigational drug product candidates, DaxibotulinumtoxinA for Injection , or RT002 injectable, and DaxibotulinumtoxinA Topical Gel (RT001), or RT001 topical.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:

Twitter Auto Publish Powered By : XYZScripts.com